{"id":14146,"date":"2023-05-08T11:12:14","date_gmt":"2023-05-08T09:12:14","guid":{"rendered":"https:\/\/udic.es\/?p=14146"},"modified":"2024-02-14T19:50:35","modified_gmt":"2024-02-14T18:50:35","slug":"positive-result-from-the-pivotal-trial-with-levodopa-administered-by-continuous-subcutaneous-infusion","status":"publish","type":"post","link":"https:\/\/udic.es\/en\/positive-result-from-the-pivotal-trial-with-levodopa-administered-by-continuous-subcutaneous-infusion\/","title":{"rendered":"Positive result from the Pivotal trial with levodopa administered by continuous subcutaneous infusion"},"content":{"rendered":"<p>Highly positive results from the pivotal Phase III BouNDless trial evaluating ND0612 in patients with Parkinson&#8217;s disease with motor fluctuations.<br \/>\nNeuroDerm, a subsidiary of Mitsubishi Tanabe Pharma, announced the positive results in January 2023 of this 24h\/d subcutaneous infusion of levodopa\/carbidopa, with a marked improvement in ON time without bothersome dyskinesias and a reduction in OFF time.<br \/>\nThis information has been sent to the regulatory authorities of the US and the European Union.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Highly positive results from the pivotal Phase III BouNDless trial evaluating ND0612 in patients with Parkinson&#8217;s disease with motor fluctuations. NeuroDerm, a subsidiary of Mitsubishi Tanabe Pharma, announced the positive results in January 2023 of this 24h\/d subcutaneous infusion of levodopa\/carbidopa, with a marked improvement in ON time without bothersome dyskinesias and a reduction in&#8230;<\/p>\n","protected":false},"author":5,"featured_media":9251,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[130],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Positive result from the Pivotal trial with levodopa administered by continuous subcutaneous infusion - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica<\/title>\n<meta name=\"description\" content=\"Highly positive results from the pivotal Phase III BouNDless trial evaluating ND0612 in patients with Parkinson&#039;s disease with motor fluctuations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/udic.es\/en\/positive-result-from-the-pivotal-trial-with-levodopa-administered-by-continuous-subcutaneous-infusion\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Positive result from the Pivotal trial with levodopa administered by continuous subcutaneous infusion - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\" \/>\n<meta property=\"og:description\" content=\"Highly positive results from the pivotal Phase III BouNDless trial evaluating ND0612 in patients with Parkinson&#039;s disease with motor fluctuations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/udic.es\/en\/positive-result-from-the-pivotal-trial-with-levodopa-administered-by-continuous-subcutaneous-infusion\/\" \/>\n<meta property=\"og:site_name\" content=\"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci%c3%b3-Cl%c3%adnica-447149502490430\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-08T09:12:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-02-14T18:50:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/udic.es\/wp-content\/uploads\/2017\/07\/logo.png\" \/>\n\t<meta property=\"og:image:width\" content=\"815\" \/>\n\t<meta property=\"og:image:height\" content=\"246\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Anais\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Anais\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/udic.es\/en\/positive-result-from-the-pivotal-trial-with-levodopa-administered-by-continuous-subcutaneous-infusion\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/udic.es\/en\/positive-result-from-the-pivotal-trial-with-levodopa-administered-by-continuous-subcutaneous-infusion\/\"},\"author\":{\"name\":\"Anais\",\"@id\":\"https:\/\/udic.es\/#\/schema\/person\/47c147b5836dcc61f2cde77c55acd6e8\"},\"headline\":\"Positive result from the Pivotal trial with levodopa administered by continuous subcutaneous infusion\",\"datePublished\":\"2023-05-08T09:12:14+00:00\",\"dateModified\":\"2024-02-14T18:50:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/udic.es\/en\/positive-result-from-the-pivotal-trial-with-levodopa-administered-by-continuous-subcutaneous-infusion\/\"},\"wordCount\":87,\"publisher\":{\"@id\":\"https:\/\/udic.es\/#organization\"},\"image\":{\"@id\":\"https:\/\/udic.es\/en\/positive-result-from-the-pivotal-trial-with-levodopa-administered-by-continuous-subcutaneous-infusion\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/07\/logo.png\",\"articleSection\":[\"Parkinson\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/udic.es\/en\/positive-result-from-the-pivotal-trial-with-levodopa-administered-by-continuous-subcutaneous-infusion\/\",\"url\":\"https:\/\/udic.es\/en\/positive-result-from-the-pivotal-trial-with-levodopa-administered-by-continuous-subcutaneous-infusion\/\",\"name\":\"Positive result from the Pivotal trial with levodopa administered by continuous subcutaneous infusion - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"isPartOf\":{\"@id\":\"https:\/\/udic.es\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/udic.es\/en\/positive-result-from-the-pivotal-trial-with-levodopa-administered-by-continuous-subcutaneous-infusion\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/udic.es\/en\/positive-result-from-the-pivotal-trial-with-levodopa-administered-by-continuous-subcutaneous-infusion\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/07\/logo.png\",\"datePublished\":\"2023-05-08T09:12:14+00:00\",\"dateModified\":\"2024-02-14T18:50:35+00:00\",\"description\":\"Highly positive results from the pivotal Phase III BouNDless trial evaluating ND0612 in patients with Parkinson's disease with motor fluctuations.\",\"breadcrumb\":{\"@id\":\"https:\/\/udic.es\/en\/positive-result-from-the-pivotal-trial-with-levodopa-administered-by-continuous-subcutaneous-infusion\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/udic.es\/en\/positive-result-from-the-pivotal-trial-with-levodopa-administered-by-continuous-subcutaneous-infusion\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/udic.es\/en\/positive-result-from-the-pivotal-trial-with-levodopa-administered-by-continuous-subcutaneous-infusion\/#primaryimage\",\"url\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/07\/logo.png\",\"contentUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/07\/logo.png\",\"width\":815,\"height\":246,\"caption\":\"logo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/udic.es\/en\/positive-result-from-the-pivotal-trial-with-levodopa-administered-by-continuous-subcutaneous-infusion\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/udic.es\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Positive result from the Pivotal trial with levodopa administered by continuous subcutaneous infusion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/udic.es\/#website\",\"url\":\"https:\/\/udic.es\/\",\"name\":\"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"description\":\"Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"publisher\":{\"@id\":\"https:\/\/udic.es\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/udic.es\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/udic.es\/#organization\",\"name\":\"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica\",\"url\":\"https:\/\/udic.es\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/udic.es\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png\",\"contentUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png\",\"width\":408,\"height\":123,\"caption\":\"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica\"},\"image\":{\"@id\":\"https:\/\/udic.es\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci\u00f3-Cl\u00ednica-447149502490430\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/udic.es\/#\/schema\/person\/47c147b5836dcc61f2cde77c55acd6e8\",\"name\":\"Anais\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/udic.es\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/7ed5cf308b81b1b2a9a240a98a4dff6d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/7ed5cf308b81b1b2a9a240a98a4dff6d?s=96&d=mm&r=g\",\"caption\":\"Anais\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Positive result from the Pivotal trial with levodopa administered by continuous subcutaneous infusion - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","description":"Highly positive results from the pivotal Phase III BouNDless trial evaluating ND0612 in patients with Parkinson's disease with motor fluctuations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/udic.es\/en\/positive-result-from-the-pivotal-trial-with-levodopa-administered-by-continuous-subcutaneous-infusion\/","og_locale":"en_US","og_type":"article","og_title":"Positive result from the Pivotal trial with levodopa administered by continuous subcutaneous infusion - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","og_description":"Highly positive results from the pivotal Phase III BouNDless trial evaluating ND0612 in patients with Parkinson's disease with motor fluctuations.","og_url":"https:\/\/udic.es\/en\/positive-result-from-the-pivotal-trial-with-levodopa-administered-by-continuous-subcutaneous-infusion\/","og_site_name":"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","article_publisher":"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci%c3%b3-Cl%c3%adnica-447149502490430\/","article_published_time":"2023-05-08T09:12:14+00:00","article_modified_time":"2024-02-14T18:50:35+00:00","og_image":[{"width":815,"height":246,"url":"https:\/\/udic.es\/wp-content\/uploads\/2017\/07\/logo.png","type":"image\/png"}],"author":"Anais","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Anais","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/udic.es\/en\/positive-result-from-the-pivotal-trial-with-levodopa-administered-by-continuous-subcutaneous-infusion\/#article","isPartOf":{"@id":"https:\/\/udic.es\/en\/positive-result-from-the-pivotal-trial-with-levodopa-administered-by-continuous-subcutaneous-infusion\/"},"author":{"name":"Anais","@id":"https:\/\/udic.es\/#\/schema\/person\/47c147b5836dcc61f2cde77c55acd6e8"},"headline":"Positive result from the Pivotal trial with levodopa administered by continuous subcutaneous infusion","datePublished":"2023-05-08T09:12:14+00:00","dateModified":"2024-02-14T18:50:35+00:00","mainEntityOfPage":{"@id":"https:\/\/udic.es\/en\/positive-result-from-the-pivotal-trial-with-levodopa-administered-by-continuous-subcutaneous-infusion\/"},"wordCount":87,"publisher":{"@id":"https:\/\/udic.es\/#organization"},"image":{"@id":"https:\/\/udic.es\/en\/positive-result-from-the-pivotal-trial-with-levodopa-administered-by-continuous-subcutaneous-infusion\/#primaryimage"},"thumbnailUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/07\/logo.png","articleSection":["Parkinson"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/udic.es\/en\/positive-result-from-the-pivotal-trial-with-levodopa-administered-by-continuous-subcutaneous-infusion\/","url":"https:\/\/udic.es\/en\/positive-result-from-the-pivotal-trial-with-levodopa-administered-by-continuous-subcutaneous-infusion\/","name":"Positive result from the Pivotal trial with levodopa administered by continuous subcutaneous infusion - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","isPartOf":{"@id":"https:\/\/udic.es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/udic.es\/en\/positive-result-from-the-pivotal-trial-with-levodopa-administered-by-continuous-subcutaneous-infusion\/#primaryimage"},"image":{"@id":"https:\/\/udic.es\/en\/positive-result-from-the-pivotal-trial-with-levodopa-administered-by-continuous-subcutaneous-infusion\/#primaryimage"},"thumbnailUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/07\/logo.png","datePublished":"2023-05-08T09:12:14+00:00","dateModified":"2024-02-14T18:50:35+00:00","description":"Highly positive results from the pivotal Phase III BouNDless trial evaluating ND0612 in patients with Parkinson's disease with motor fluctuations.","breadcrumb":{"@id":"https:\/\/udic.es\/en\/positive-result-from-the-pivotal-trial-with-levodopa-administered-by-continuous-subcutaneous-infusion\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/udic.es\/en\/positive-result-from-the-pivotal-trial-with-levodopa-administered-by-continuous-subcutaneous-infusion\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/udic.es\/en\/positive-result-from-the-pivotal-trial-with-levodopa-administered-by-continuous-subcutaneous-infusion\/#primaryimage","url":"https:\/\/udic.es\/wp-content\/uploads\/2017\/07\/logo.png","contentUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/07\/logo.png","width":815,"height":246,"caption":"logo"},{"@type":"BreadcrumbList","@id":"https:\/\/udic.es\/en\/positive-result-from-the-pivotal-trial-with-levodopa-administered-by-continuous-subcutaneous-infusion\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/udic.es\/en\/"},{"@type":"ListItem","position":2,"name":"Positive result from the Pivotal trial with levodopa administered by continuous subcutaneous infusion"}]},{"@type":"WebSite","@id":"https:\/\/udic.es\/#website","url":"https:\/\/udic.es\/","name":"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","description":"Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","publisher":{"@id":"https:\/\/udic.es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/udic.es\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/udic.es\/#organization","name":"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica","url":"https:\/\/udic.es\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/udic.es\/#\/schema\/logo\/image\/","url":"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png","contentUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png","width":408,"height":123,"caption":"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica"},"image":{"@id":"https:\/\/udic.es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci\u00f3-Cl\u00ednica-447149502490430\/"]},{"@type":"Person","@id":"https:\/\/udic.es\/#\/schema\/person\/47c147b5836dcc61f2cde77c55acd6e8","name":"Anais","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/udic.es\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7ed5cf308b81b1b2a9a240a98a4dff6d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7ed5cf308b81b1b2a9a240a98a4dff6d?s=96&d=mm&r=g","caption":"Anais"}}]}},"_links":{"self":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/posts\/14146"}],"collection":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/comments?post=14146"}],"version-history":[{"count":1,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/posts\/14146\/revisions"}],"predecessor-version":[{"id":14147,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/posts\/14146\/revisions\/14147"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/media\/9251"}],"wp:attachment":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/media?parent=14146"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/categories?post=14146"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/tags?post=14146"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}